First-Line Afatinib starting dose of 30 mg versus 40 mg in advanced non-small cell lung cancer with uncommon EGFR mutations: A retrospective comparative study from Vietnam
Journal of Oncology Pharmacy Practice · 19.11.2026
DOI: 10.1177/10781552261509992 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 19.11.2026. Verfasst von Anh Tuan Nguyen und 4 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Afatinib is a first-line option for non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations, but the optimal starting dose remains unclear, particularly in Southeast Asian populations. We compared clinical outcomes of a reduced 30 mg starting dose versus the standard 40 mg dose.
Methods
We retrospectively analyzed 78 patients with uncommon EGFR-mutated NSCLC (59 started at afatinib 30 mg/day, 19 at 40 mg/day) at Vietnam National Cancer Hospital (2018–2024). The starting dose was selected by the treating physician, and subsequent dose adjustment was permitted. Primary endpoints were progression-free survival (PFS) and objective response rate (ORR); secondary endpoints were disease control rate (DCR), overall survival (OS), and safety. Median follow-up was 19.7 months.
Results
ORR was 67.8% (30 mg) versus 63.2% (40 mg; p = 0.782); DCR was 86.4% versus 68.4% (p = 0.092). Median PFS was 10.9 vs 11.4 months (hazard ratio [HR] for 40 mg vs 30 mg, 0.88; 95% confidence interval [CI] 0.48–1.63; p = 0.688); median OS was 25.5 vs 23.1 months (HR 1.06, 95%CI 0.50–2.24; p = 0.881). Diarrhea (57.7%), rash (50.0%), and paronychia (28.2%) were the most common adverse events. Any-grade diarrhea occurred in 57.6% (30 mg) and 57.9% (40 mg) (p = 1.000). Grade ≥3 diarrhea (3.4% vs 15.8%; p = 0.090) and any grade ≥ 3 toxicity (8.5% vs 15.8%; p = 0.395) were numerically less frequent with 30 mg, but neither difference was statistically significant; any-grade toxicity was similar (84.7% vs 89.5%). Dose reduction at any time was less frequent with 30 mg (11.9% vs 42.1%; p = 0.007); among only the patients who underwent a reduction (n = 6 vs n = 8 with a recorded date), the median time to first reduction was 141 vs 39 days. In the 30 mg group, 12 patients escalated to 40 mg.
Conclusion
In this retrospective cohort, no statistically significant differences in ORR, DCR, PFS, or OS were observed between afatinib starting doses of 30 mg and 40 mg, and overall toxicity was similar. A 30 mg starting dose was associated with fewer dose reductions, which does not by itself indicate a superior safety profile. Prospective studies are needed to define the optimal starting dose in patients with uncommon EGFR mutations, particularly in lower body size and in settings with limited toxicity monitoring.
Zitieren
APA
Nguyen, A. T., Vu, T. H., Nguyen, H. T. T., Ta, T. V., & Truong, M. C. (2026). First-Line Afatinib starting dose of 30 mg versus 40 mg in advanced non-small cell lung cancer with uncommon EGFR mutations: A retrospective comparative study from Vietnam. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261509992
Vancouver
Nguyen AT, Vu TH, Nguyen HTT, Ta TV, Truong MC. First-Line Afatinib starting dose of 30 mg versus 40 mg in advanced non-small cell lung cancer with uncommon EGFR mutations: A retrospective comparative study from Vietnam. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552261509992
BibTeX
@article{Nguyen2026,
author = {Nguyen, Anh Tuan and Vu, Thanh Ha and Nguyen, Hoa Thai Thi and Ta, To Van and Truong, Minh Cong},
title = {First-Line Afatinib starting dose of 30 mg versus 40 mg in advanced non-small cell lung cancer with uncommon EGFR mutations: A retrospective comparative study from Vietnam},
journal = {Journal of Oncology Pharmacy Practice},
year = {2026},
doi = {10.1177/10781552261509992}
}
EUVIMED